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time around, we have been aided by pure good luck. The 
virus did not mutate during the pandemic to a more lethal 
form. Widespread resistance to oseltamivir did not develop. 
The vaccine proved to be a good match with circulating 
viruses and showed an excellent safety profi le”. 3
In more developed countries, this is a moment of balance. 
Of what went right and what went wrong, what was done 
well and what could have been done better. Portugal was no 
exception and the impact of the infl uenza A (H1N1) 2009 was 
also felt in the country. Moreover, there is a duty and a sense 
of responsibility in Portugal to assess and analyze what was 
done and their motives, in addition to transparency and 
“accountability”, include respect for bereaved families and 
the obligation to learn from our own mistakes so as to do 
better in future pandemics.
In Portugal, influenza A had a similar behaviour to that 
of other European countries and has been well described 
in the following words by Dunning and Openshaw: “A 
generally mild disease that sometimes killed”. The National 
Contingency Plan was activated on 24th April 2009 and 
the first case was diagnosed on the 29th of the same 
month. The estimated overall attack rate was 10 to 15 %, 
representing a high underreporting, and the peak of activity 
occurred during the second half of November 2009 (weeks 
47 and 48). Despite the benevolence of most situations, 
in some cases, there were serious disease types, having 
been reported 124 laboratory-confi rmed deaths, 5 the fi rst 
of which occurred on 23th September 2009. The average 
age of deceased patients was 47.6 years with a slight male 
predominance (60 %) compared to females (40 %). Infl uenza 
was responsible for deaths in all age groups, with the 
highest incidence between age 15 and 64, being that 87 % 
were under 65 years old. The minimum and maximum age 
of deceased patients corresponds to 5 months and 88 years 
accordingly. 5 It is important to note that this age distribution 
differs signifi cantly from that found in seasonal infl uenza, 
in which more than 80 % of deaths occur in patients aged 
75 years or over. 6
EDITORIAL
A year and two months of 2009 infl uenza pandemic
Um ano e dois meses de pandemia de gripe 2009
The pandemic infl uenza A (H1N1) 2009 lasted 425 days. In 
other words, 14 months elapsed since the announcement of 
its beginning on 11th June 2009 and its end on 10th August 
2010. It was the fi rst time that a pandemic was announced in 
this century and 40 years since the past 1968-1969 pandemic 
known as the “Hong Kong Flu”. Mrs. Margaret Chan, M.D., 
Director-General of the World Health Organization (WHO), 
will certainly never forget the words she stated on 11th 
June 2009: “The world is now at the start of 2009 infl uenza 
pandemic”. 1
Up until the beginning of August 2010, more than 
214 countries had reported cases of pandemic influenza 
and at least 18 449 deaths, of which approximately 
5 000 in the European region. 2 Unlike past pandemics, only 
laboratory-confi rmed deaths were counted, representing a 
default value of the real impact of the pandemic.
Infl uenza activity is still reported in some countries, but 
only at a local level and within the expected values for the 
season. That is, with no regional or global dimension and 
no activity outside the seasonal influenza season, which 
characterized phase 6 of the pandemic. Similarly, it appears 
that the pandemic strain is no longer dominant and that 
about 20 to 40 % of the population in different continents 
show some level of immunity. 3
These were the main reasons that led the WHO to 
justify their statement of 10th August 2010, whereby it was 
declared that we are now moving into the post-pandemic 
period and the new H1N1 virus has largely run its course. 3 
Other paragraphs in this statement are worth mentioning: 
“We expect the H1N1 virus to take on the behaviour of 
a seasonal influenza virus and continue to circulate for 
some years to come. (...) Based on available evidence and 
experience from past pandemics, it is likely that the virus 
will continue to cause serious disease in younger age groups, 
at least in the immediate post-pandemic period. Groups 
identifi ed during the pandemic as at higher risk of severe or 
fatal illness will probably remain at heightened risk, though 
hopefully the number of such cases will diminish. (...) This 
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Approximately 1/3 of deceased patients were healthy and, 
as concerns the 2/3 presenting risk factors for severe disease, 
chronic respiratory diseases were the most prevalent risk 
factor, having been diagnosed in 25 % of the cases. 5 Morbid 
obesity was present in 10 % of deceased patients with risk 
factors 5. The main cause of death in 80 % of deceased patients 
and in all age groups was pneumonia caused by the infl uenza 
virus, the primary viral pneumonia. 5 Moreover, the cause of 
death was another signifi cant difference compared to seasonal 
influenza, in which the majority of deaths results from 
decompensation of comorbidities or bacterial pneumonia.
For the first time in the history of humanity, a vaccine 
was developed and made available during a pandemic. In 
Portugal, vaccination began on 26th October 2009, curiously 
2 to 3 weeks before the peak of activity of the fi rst pandemic 
wave. Unfortunately and worthy of refl ection on the part of all 
healthcare professionals, none of the deceased patients with 
risk factors and indication for vaccination were vaccinated or 
completed the vaccine schedule. Meanwhile, the hundreds 
of millions of pandemic vaccines that were administered 
substantiate the results of safety and effectiveness of the initial 
clinical trials, conducted according to the usual methodology 
and required for the licensing of any medication. Moreover, they 
also confi rm the imprudence, ignorance and lack of scientifi c 
evidence of the campaign against the pandemic vaccine, 
so widespread in the media, a factor which, in our opinion, 
contributed to the low rate of adherence to vaccination and, 
most likely, to excess mortality in our country.
The 124 deaths in Portugal accounted for a mortality 
rate of 1.17 per 100 000 inhabitants. Albeit below the 
maximum values observed in EU countries, this fi gure ranks 
Portugal above the average mortality recorded in those 
countries (Figure 1) and the same is true when compared 
with the estimated mortality rate in the United States 
(0.97/100 000 inhabitants). 7
One of the major problems identifi ed in most countries 
was the diffi culty in conveying the message that although 
in the majority of cases the clinical picture was benign, a 
small percentage of patients, even the previously healthy 
ones, could develop into extremely severe forms of illness. 
The countries with the best results were those who were 
more effi cient in the prevention of the disease in individuals 
with risk factors (e.g.: through vaccination) and/or early 
diagnosis of severe patients or aggravation of the disease, 
in order to start antiviral therapy as soon as possible.
In conclusion, we consider it reasonable to conclude that 
the action of national health authorities was, in essence, 
proper and adequate, although with a few unexpected 
difficulties in communicating risk and uncertainty, both 
among the population and health professionals. There is 
a collective duty to do even better in the future without 
necessarily spending more resources. And we hope the 
relative benignity of the current pandemic strain does not 
promote a false sense of security with negative consequences 
for planning and preparing similar cases in the future. 4
In this issue of the Revista Portuguesa de Pneumologia 
are published two articles on the impact of pandemic 
influenza in Portugal. The article “Pandemic influenza A 
(H1N1) in the North of Portugal: how did the Autumn-Winter 
wave behave?” by Ana Correia and colleagues 8 present an 
overview of the characteristics of the pandemic wave in 
the North of Portugal and emphasize the importance of 
pursuing and reinforcing influenza surveillance. Vítor 
Duque and colleagues publish an article on “The Early Days 
of Pandemic (H1N1) 2009 Virus Infection in the Central 
Region of Portugal”, 9 in which they present the clinical and 
Figure 1 Mortality rates per 100 000 inhabitants by the infl uenza A (H1N1) 2009 in EU and EFTA countries from 28th April 2009 to 
28th April 2010 (European Centre for Disease Prevention and Control, 2010)
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epidemiological characterization of the fi rst 255 confi rmed 
cases diagnosed in the Central Region of the country during 
the period from June to August 2009. In an initial phase of 
the pandemic with more questions than answers, namely on 
the characteristics of this new microorganism, the authors 
stress the importance of early diagnosis and isolation 
measures in infection control, as well as the impact of the 
main roads and highways in the spread of the disease. In 
addition to the scientific value, these two articles have 
major historical interest, in the future.
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